Dan Leonard Named Executive Director of We Work For Health

NEWS
- Jul 7
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on...
- Jun 14
New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem
- Nov 21
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
- Nov 16
Maryland, learn from Colorado: Price controls on drugs can do more harm than good
- Nov 7
Guest commentary: Government price setting could hurt patient access and economy
- Nov 2
How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation
- Oct 31
We Work For Health Statement on USITC's Report on TRIPS Waiver Expansion
- Oct 30
The Pill Penalty, Patients and Policymakers
- Oct 23
Pharma Industry Readies for Drug Pricing Lawsuit Second Wave
- Oct 10
Vital Health Podcast
- Sep 28
Voters Will Reject Inflation Reduction Act’s Assault on Medicare
- Sep 18
Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
- Sep 17
To Really Impact Healthcare Costs Look Beyond Drug Prices
- Sep 10
New Drug Pricing Policies Will Come at Great Expense
- Sep 10
The Inflation Reduction Act Will Lead to Fewer New Medicines
- Sep 5
AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem
- Aug 31
Commentary: What impact the Inflation Reduction Act can have on Boston biotechs
- Aug 29
We Work For Health Statement on Release of CMS’ Prescription Drug Negotiation List
- Aug 28
The High Cost of Price Controls on Eliquis and Other Drugs
- Aug 28
HHS Drops First 10 Drugs for Medicare Drug Price Negotiation
- Aug 28
Biden administration chooses first 10 drugs for Medicare price negotiations
- Aug 27
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
- Aug 27
U.S. Chamber: Biden Administration Rushes to Implement Drug Price Control Scheme...
- Aug 8
Dan Leonard Named Executive Director of We Work For Health
- Aug 7
Opinion: This plan to cut drug prices could result in lost jobs and fewer medicines. Here’s why
- Aug 3
Government Needs to Encourage – Not Suppress – Drug Competition
- Jul 27
Roche: Have Abandoned Some Trials Due to U.S. Drug Pricing Plans
- Jul 26
Attempts to Expand on Prescription Drug Price Controls Put American Workers, Patients at Risk
- Jul 7
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on...
- Jul 5
Genentech CEO Alexander Hardy warns of 'unintended consequences' from the Inflation Reduction Act
- Jun 27
On conference circuit, biotechs lobby for their identity as new IRA drug pricing reforms take hold
- Jun 20
Biopharma Execs Weigh Controversial Move: Opting Out of Medicare to Escape Drug Price Negotiations
- Jun 15
Inflation Reduction Act is destabilizing investment in drug innovation, execs say
- Jun 14
New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem
- Jun 13
IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says
- Jun 4
Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
- Jun 1
IRA forcing pharmas to leave cancer patients in the lurch, CEOs say
- May 18
Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
- May 8
Statement By We Work For Health on Ways & Means Hearing
- Mar 16
Amgen cites inflation, pressure on drug prices in 450-person layoff
- Mar 9
Statement By We Work For Health on Biden Administration Budget Release
- Feb 8
Statement By We Work For Health on State of the Union Address
- Feb 7
Fix the IRA Before its Unintended Consequences Harm Patients and Workers
- Jan 5
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones
- Nov 20, 2022
Bristol Myers Squibb warns US price reforms will dent drug development
- Oct 31, 2022
Eli Lilly blames Biden's IRA for cancer drug discontinuation as the new pharma playbook takes shape
- Oct 26, 2022
As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis
- Oct 20, 2022
Congressional User Fees Agreement Marks a Step Forward for Patients and Innovators
- Aug 4, 2022
A Blown Play: When Congress Treats Patients Like a Political Football, We all Lose
- Jul 31, 2022
The Far-Reaching Health, Economic & Innovation Impact of Harmful Government Price Setting Policies